Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
Type:
Grant
Filed:
February 13, 2018
Date of Patent:
December 7, 2021
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
November 23, 2021
Assignee:
Immunomedics, Inc.
Inventors:
David M. Goldenberg, William A. Wegener
Abstract: Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.
Type:
Grant
Filed:
November 4, 2015
Date of Patent:
November 16, 2021
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Richard J. O'Reilly, Ekaterina Doubrovina, Guenther Koehne, Aisha N. Hasan, Susan E. Prockop
Abstract: The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.
Type:
Grant
Filed:
June 6, 2016
Date of Patent:
October 26, 2021
Assignee:
Board of Regents, The University of Texas System
Inventors:
Katy Rezvani, Elizabeth Shpall, Enli Liu
Abstract: Provided herein are methods of making a detectably-labeled, soluble MHC molecule that can be used in a novel Kon-rate assay and an improved TCR ligand koff-rate assay.
Abstract: The present invention provides a cytokine-based culture method for ex vivo expansion of NK cells from postembryonic hematopoietic stem cells into a fully closed, large-scale, cell culture bioprocess. We optimized enrichment of CD34+ cells followed by efficient expansion in gas-permeable cell culture bags. Thereafter, expanded CD34+ cells could be reproducibly amplified and differentiated into CD56+CD3? NK cell products with a mean expansion of more than 2,000 fold and a purity of >90%. Also provided are collections of cultured cells having specific properties.
Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands. This application further relates to modified ?1-?2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
September 14, 2021
Assignee:
XYPHOS BIOSCIENCES INC.
Inventors:
Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin, Jr., Dana Gebhart, Tarah Baron
Abstract: The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.
Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
Type:
Grant
Filed:
June 29, 2015
Date of Patent:
August 10, 2021
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.
Type:
Grant
Filed:
August 4, 2014
Date of Patent:
April 20, 2021
Assignees:
Life Sciences Research Partners VZW, Katholieke Universiteit Leuven
Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
Type:
Grant
Filed:
December 30, 2008
Date of Patent:
April 6, 2021
Assignee:
Agilent Technologies, Inc.
Inventors:
Jørgen Schøller, Liselotte Brix, Henrik Pedersen
Abstract: This disclosure provides compositions and methods for the activation and expansion of human T cells or NK cells using soluble monospecific antibody complexes.
Abstract: The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.
Type:
Grant
Filed:
January 30, 2013
Date of Patent:
January 26, 2021
Assignees:
LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
Abstract: The present invention provides modified natural killer T (NKT) cells, pharmaceutical compositions comprising the modified NKT cells and at least one pharmaceutically acceptable carrier or excipient, and uses of the modified NKT cells. Also disclosed herein are methods for enriching NKT cells and generating the modified natural killer T cells.
Abstract: Compositions that include one isolated, class I HLA-E trimolecular complex that includes a peptide ligand unique to M. tuberculosis-infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three components are also disclosed.
Type:
Grant
Filed:
March 27, 2015
Date of Patent:
December 8, 2020
Assignees:
The Board of Regents of the University of Oklahoma, Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
Inventors:
William H. Hildebrand, Curtis McMurtrey, David Lewinsohn, Deborah Lewinsohn, Melanie Harriff
Abstract: MICA and MICB are expressed on the surface of stressed, virus infected and cancer cells; they bind to their common receptor NKG2D on immune effector cells such as natural killer (NK) cells and some T cells to signal immune responses, including cytotoxicity, towards cells expressing surface MICA or MICB. To evade this immune-surveillance, virus infected cells and cancer cells shed the extracellular domain of their MICA and MICB as soluble forms (sMICA and sMICB) which act as decoys by binding and down-regulating expression of NKG2D on the immune effector cells. Antibodies are provided that specifically bind the soluble forms of both MICA and MICB to inhibit their adverse effects, but do not bind cell- or membrane-bound MICA and MICB to preserve their beneficial immune effects.
Abstract: The methods, compositions, and assays described herein are based, in part, on the discovery that CD1a mediates inflammation related to certain conditions such as urushiol exposure, psoriasis and other inflammatory skin diseases. One aspect provided herein relates to a method for treating or preventing an inflammatory skin disease, the method comprising: administering a therapeutically effective amount of an inhibitor of CD 1a to a subject having an inflammatory skin disease, thereby treating or preventing the inflammatory skin diseases.
Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.
Type:
Grant
Filed:
October 7, 2016
Date of Patent:
November 17, 2020
Assignees:
IMMATICS BIOTECHNOLOGIES GMBH, MORPHOSYS AG
Inventors:
Andrea Mahr, Toni Weinschenk, Dominik Maurer, Claudia Wagner, Klaus Felix Hartlepp, Alexandra Kraus
Abstract: The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the ?-chain region of the T cell receptor gene rearranged to uniform V?-J? in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the ?-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V?-J?. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
Abstract: Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.
Type:
Grant
Filed:
November 13, 2015
Date of Patent:
October 27, 2020
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Richard W. Childs, Mattias C.V. Carlsten